PE20050229A1 - Derivados de etinilprolina - Google Patents

Derivados de etinilprolina

Info

Publication number
PE20050229A1
PE20050229A1 PE2004000589A PE2004000589A PE20050229A1 PE 20050229 A1 PE20050229 A1 PE 20050229A1 PE 2004000589 A PE2004000589 A PE 2004000589A PE 2004000589 A PE2004000589 A PE 2004000589A PE 20050229 A1 PE20050229 A1 PE 20050229A1
Authority
PE
Peru
Prior art keywords
amide
phenyl
compounds
derivatives
morpholin
Prior art date
Application number
PE2004000589A
Other languages
English (en)
Inventor
Bertram Cezanne
Dieter Dorsch
Christos Tsaklakidis
Werner Mederski
Johannes Gleitz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10327428A external-priority patent/DE10327428A1/de
Priority claimed from DE10329457A external-priority patent/DE10329457A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20050229A1 publication Critical patent/PE20050229A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A COMPUESTOS DE FORMULA I DONDE R ES H, ARILO, ARILALQUILO, ENTRE OTROS; R1 ES H, =O, F, Br, ENTRE OTROS; R2 ES H, F, Br, I, ENTRE OTROS; R3 ES HETEROCICLO MONOCICLICO (C1-C4) SATURADO, INSATURADO O AROMATICO, ENTRE OTROS; O JUNTOS, R2 Y R3 SON -CH=CH-NH-, -CH2-CH2-NH. TAMBIEN REFERIDO A UN PROCEDIMIENTO PARA PREPARAR ESTOS COMPUESTOS, SUS DERIVADOS, SALES, SOLVATOS Y ESTEREOISOMEROS CUYOS PREFERIDOS SON: 1-[(4-ETINIL-FENIL)-AMIDA]-2-{[4-(6-METIL-3-OXO-MORFOLIN-4-IL)-FENIL]-AMIDA} DEL ACIDO (2R,4R)-4-(CARBOXIMETOXI)-PIRROLIDIN-1,2-DICARBOXILICO; 1-[(4-ETINIL-FENIL)-AMIDA]-2-{[4-(3-OXO-MORFOLIN-4-IL)-FENIL]-AMIDA} DEL ACIDO (2R,4R)-4-(2,3-DIHIDROXI-PROPOXI)-PIRROLIDIN-1,2-DICARBOXILICO; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DEL FACTOR DE COAGULACION Xa UTILES EN LA PROFILAXIS Y/O TERAPIA DE ENFERMEDADES TROMBOEMBOLICAS Y TRATAMIENTO DE TUMORES
PE2004000589A 2003-06-18 2004-06-14 Derivados de etinilprolina PE20050229A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10327428A DE10327428A1 (de) 2003-06-18 2003-06-18 Ethinylprolinderivate
DE10329457A DE10329457A1 (de) 2003-04-03 2003-07-01 Ethinylprolinderivate

Publications (1)

Publication Number Publication Date
PE20050229A1 true PE20050229A1 (es) 2005-04-12

Family

ID=33553467

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000589A PE20050229A1 (es) 2003-06-18 2004-06-14 Derivados de etinilprolina

Country Status (16)

Country Link
US (1) US7557222B2 (es)
EP (1) EP1633346B1 (es)
JP (1) JP5015593B2 (es)
KR (1) KR20060023154A (es)
CN (1) CN1809346A (es)
AR (1) AR044818A1 (es)
AT (1) ATE337000T1 (es)
AU (1) AU2004246766B2 (es)
BR (1) BRPI0411466A (es)
CA (1) CA2529453C (es)
DE (1) DE502004001289D1 (es)
ES (1) ES2271894T3 (es)
MX (1) MXPA05013536A (es)
PE (1) PE20050229A1 (es)
TW (1) TW200504012A (es)
WO (1) WO2004110433A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004004731A1 (de) * 2004-01-30 2005-08-18 Merck Patent Gmbh Harnstoffderivate
DE102004016605A1 (de) * 2004-04-03 2005-10-20 Merck Patent Gmbh Thiocarbamoylproline
JP2009515925A (ja) * 2005-11-16 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー 凝固第Ｘａ因子のインヒビターとしての新規なピロリジン誘導体
EP1818330A1 (de) * 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
WO2007131982A2 (de) 2006-05-16 2007-11-22 Boehringer Ingelheim International Gmbh Substituierte prolinamide, deren herstellung und deren verwendung als arzneimittel
MX2009013952A (es) 2007-06-28 2010-01-28 Novartis Ag Moduladores de calicreina 7.
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
RU2014110401A (ru) 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
WO2013039802A1 (en) 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066717A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
EP2925322B1 (en) 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2934533B1 (en) 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2956142B1 (en) 2013-02-18 2017-09-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014150132A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6337750B2 (ja) * 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
CN106103453A (zh) * 2014-01-14 2016-11-09 大日本住友制药株式会社 缩合5‑噁唑烷酮衍生物
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
CN109796439B (zh) * 2019-01-18 2020-05-19 西安交通大学 一种羟脯氨酸类肽衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776053B2 (en) * 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
DE60221505D1 (de) * 2001-03-30 2007-09-13 Millennium Pharm Inc FAKTOR Xa BENZAMIDIN INHIBITOREN
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate

Also Published As

Publication number Publication date
AR044818A1 (es) 2005-10-05
US7557222B2 (en) 2009-07-07
AU2004246766B2 (en) 2009-09-17
KR20060023154A (ko) 2006-03-13
DE502004001289D1 (de) 2006-10-05
CN1809346A (zh) 2006-07-26
TW200504012A (en) 2005-02-01
BRPI0411466A (pt) 2006-07-11
EP1633346A1 (de) 2006-03-15
US20070093472A1 (en) 2007-04-26
ATE337000T1 (de) 2006-09-15
EP1633346B1 (de) 2006-08-23
CA2529453A1 (en) 2004-12-23
MXPA05013536A (es) 2006-03-09
WO2004110433A1 (de) 2004-12-23
CA2529453C (en) 2012-10-02
JP5015593B2 (ja) 2012-08-29
ES2271894T3 (es) 2007-04-16
JP2006527708A (ja) 2006-12-07
AU2004246766A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
PE20050229A1 (es) Derivados de etinilprolina
PE20050121A1 (es) Acidos tienil-hidroxamicos, sustituidos referidos a la actividad enzimatica de la histona desacetilasa
EP1318140B9 (en) Novel amide derivatives and medicinal use thereof
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
NO20084182L (no) GSK-3 inhibitorer for behandling av osteoporose
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20030968A1 (es) Derivados de 5-feniltiazol como inhibidores de cinasas
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
NO20052487L (no) 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
PE20030612A1 (es) Benzoimidazoles
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
NO20055977L (no) Nye benzimidazolderivater
ATE475652T1 (de) Chinazolinderivate
PE20090727A1 (es) DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7
ATE359271T1 (de) Phenylderivate
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
ATE384058T1 (de) Thiazolderivate
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
PE20040666A1 (es) Derivados novedosos de piperidina
PE20061155A1 (es) Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
CY1109085T1 (el) Νεα αλατα
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
DE602004014484D1 (de) Verwendung von azetidincarboxamidderivaten in therapie

Legal Events

Date Code Title Description
FC Refusal